Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?

Claire Vanpouille-Box; Silvia C Formenti

doi:10.1016/j.it.2018.03.002

Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?

Trends Immunol. 2018 Jun;39(6):435-437. doi: 10.1016/j.it.2018.03.002. Epub 2018 Mar 26.

Authors

Claire Vanpouille-Box¹, Silvia C Formenti²

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. Electronic address: clv2002@med.cornell.edu.
² Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA. Electronic address: silvia.formenti@med.cornell.edu.

Abstract

Tumors that elude infiltration by CD8⁺ T lymphocytes are particularly resistant to multiple forms of treatment, including immune checkpoint blockade. Stromal transforming growth factor (TGF)-β appears to play a key role in this process, potentially constituting a target for novel combinatorial regimens tackling immune-excluded neoplasms.

Keywords: PD-1; atezolizumab; microsatellite instability; mutational burden; tumor neoantigens; tumor organoids.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

CD8-Positive T-Lymphocytes
Colonic Neoplasms
Humans
Immune Evasion*
Transforming Growth Factor beta*
Transforming Growth Factors

Substances

Transforming Growth Factor beta
Transforming Growth Factors

Grants and funding

S10 RR027619/RR/NCRR NIH HHS/United States